<DOC>
	<DOCNO>NCT01480479</DOCNO>
	<brief_summary>This 2-arm , randomize , phase III study investigate efficacy safety addition rindopepimut ( experimental cancer vaccine may act promote anti-cancer effect patient tumor express EGFRvIII protein ) current standard care ( temozolomide ) patient recently diagnose glioblastoma , type brain cancer . All patient administer temozolomide , standard treatment glioblastoma . Half patient randomly assign receive rindopepimut half patient randomly assign receive control call keyhole limpet hemocyanin . Patients treat blinded fashion ( neither patient doctor know arm study patient ) . Patients treated disease progression intolerance therapy patient follow survival .</brief_summary>
	<brief_title>Phase III Study Rindopepimut/GM-CSF Patients With Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description>The purpose research study find whether add experimental vaccine call rindopepimut ( also know CDX-110 ) commonly use chemotherapy drug temozolomide help improve life expectancy patient newly diagnose , resect EGFRvIII positive glioblastoma . The duration participation study may 5 year . After screen enrol study , administer temozolomide either rindopepimut/GM-CSF KLH either disease progression intolerance medication . If tumor progress study , doctor may treat therapy part study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Inclusion Criteria Among criterion , patient must meet following condition eligible study : 1 . Adult patient , ≥ 18 year old 2 . Newly diagnose glioblastoma 3 . Attempted surgical resection follow conventional chemoradiation 4 . Documented EGFRvIII positive tumor status Sponsor designate laboratory 5 . No evidence progressive disease postoperative period postchemoradiation period 6 . Candidate , agree receive , adjuvant ( maintenance ) temozolomide therapy 7 . Systemic corticosteroid therapy ≤2 mg dexamethasone equivalent per day least 3 day prior randomization 8 . WHOECOG Performance Status ≤ 2 9 . Patients childbearing/reproductive potential instruct use birth control define doctor . Exclusion Criteria Among criterion , patient meet follow condition NOT eligible study : 1 . Stereotactic biopsy ( without surgical resection ) 2 . Presence diffuse leptomeningeal disease , gliomatosis cerebri , infratentorial disease . 3 . History , presence , suspicion metastatic disease 4 . Patients receive additional treatment glioblastoma , aside surgical resection chemoradiation temozolomide 5 . Active systemic infection require treatment 6 . History malignancy ( glioblastoma ) last three year except nonmelanoma skin cancer , situ cervical cancer , treat superficial bladder cancer , cure , earlystage prostate cancer patient PSA level less ULN , carcinoma situ adequately treat cured . 7 . Planned major surgery 8 . Evidence current drug alcohol abuse 9 . Known allergy hypersensitivity keyhole limpet hemocyanin ( KLH ) , GMCSF ( sargramostim ; LEUKINE® ) , polysorbate 80 yeast derived product , history anaphylactic reaction shellfish protein 10 . Severe acute chronic medical psychiatric condition laboratory abnormality could increase risk associate participate clinical trial 11 . Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>EGFRvIII</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Small cell</keyword>
	<keyword>Giant cell</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>oligodendroglial</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>Tumor</keyword>
	<keyword>temozolomide</keyword>
	<keyword>EGFR variant III</keyword>
</DOC>